OCUL PE Ratio & Valuation,Is OCUL Overvalued

OCUL Relative Valuation

OCUL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OCUL is overvalued; if below, it's undervalued.

Historical Valuation

Ocular Therapeutix Inc (OCUL) is now in the Overvalued zone, suggesting that its current forward PS ratio of 41.74 is considered Overvalued compared with the five-year average of -10.46. The fair price of Ocular Therapeutix Inc (OCUL) is between 1.42 to 6.21 according to relative valuation methord. Compared to the current price of 11.38 USD , Ocular Therapeutix Inc is Overvalued By 83.36%.

Relative Value

Fair Zone

1.42-6.21

Current Price：11.38

83.36%

Overvalued

-8.49

-7.87

EV/EBITDA

Ocular Therapeutix Inc. (OCUL) has a current EV/EBITDA of -7.87. The 5-year average EV/EBITDA is -6.25. The thresholds are as follows: Strongly Undervalued below -14.18, Undervalued between -14.18 and -10.21, Fairly Valued between -2.28 and -10.21, Overvalued between -2.28 and 1.68, and Strongly Overvalued above 1.68. The current Forward EV/EBITDA of -7.87 falls within the Historic Trend Line -Fairly Valued range.

-7.35

EV/EBIT

Ocular Therapeutix Inc. (OCUL) has a current EV/EBIT of -7.35. The 5-year average EV/EBIT is -6.54. The thresholds are as follows: Strongly Undervalued below -15.70, Undervalued between -15.70 and -11.12, Fairly Valued between -1.96 and -11.12, Overvalued between -1.96 and 2.62, and Strongly Overvalued above 2.62. The current Forward EV/EBIT of -7.35 falls within the Historic Trend Line -Fairly Valued range.

41.74

Ocular Therapeutix Inc. (OCUL) has a current PS of 41.74. The 5-year average PS is 14.64. The thresholds are as follows: Strongly Undervalued below -7.31, Undervalued between -7.31 and 3.66, Fairly Valued between 25.61 and 3.66, Overvalued between 25.61 and 36.58, and Strongly Overvalued above 36.58. The current Forward PS of 41.74 falls within the Strongly Overvalued range.

-10.18

P/OCF

Ocular Therapeutix Inc. (OCUL) has a current P/OCF of -10.18. The 5-year average P/OCF is -9.68. The thresholds are as follows: Strongly Undervalued below -19.23, Undervalued between -19.23 and -14.46, Fairly Valued between -4.91 and -14.46, Overvalued between -4.91 and -0.14, and Strongly Overvalued above -0.14. The current Forward P/OCF of -10.18 falls within the Historic Trend Line -Fairly Valued range.

-11.20

P/FCF

Ocular Therapeutix Inc. (OCUL) has a current P/FCF of -11.20. The 5-year average P/FCF is -9.65. The thresholds are as follows: Strongly Undervalued below -24.24, Undervalued between -24.24 and -16.95, Fairly Valued between -2.35 and -16.95, Overvalued between -2.35 and 4.95, and Strongly Overvalued above 4.95. The current Forward P/FCF of -11.20 falls within the Historic Trend Line -Fairly Valued range.

Ocular Therapeutix Inc (OCUL) has a current Price-to-Book (P/B) ratio of 8.01. Compared to its 3-year average P/B ratio of 19.97 , the current P/B ratio is approximately -59.90% higher. Relative to its 5-year average P/B ratio of 15.40, the current P/B ratio is about -48.01% higher. Ocular Therapeutix Inc (OCUL) has a Forward Free Cash Flow (FCF) yield of approximately -7.92%. Compared to its 3-year average FCF yield of -13.49%, the current FCF yield is approximately -41.29% lower. Relative to its 5-year average FCF yield of -13.40% , the current FCF yield is about -40.89% lower.

8.01

P/B

Median3y

19.97

Median5y

15.40

-7.92

FCF Yield

Median3y

-13.49

Median5y

-13.40

Competitors Valuation Multiple

The average P/S ratio for OCUL's competitors is 9.89, providing a benchmark for relative valuation. Ocular Therapeutix Inc Corp (OCUL) exhibits a P/S ratio of 41.74, which is 322.04% above the industry average. Given its robust revenue growth of -5.71%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of OCUL increased by 49.35% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -236.58 to -477.30.

The secondary factor is the Revenue Growth, contributed -5.71%to the performance.

Overall, the performance of OCUL in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-5.71%

15.43M → 14.54M

Revenue Growth

101.75%

-236.58 → -477.30

Margin Expansion

-46.69%

-15.41 → -8.22

P/E Change

49.35%

7.70 → 11.50

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Ocular Therapeutix Inc (OCUL) currently overvalued or undervalued?

What is Ocular Therapeutix Inc (OCUL) fair value?

OCUL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Ocular Therapeutix Inc (OCUL) is between 1.42 to 6.21 according to relative valuation methord.

How does OCUL's valuation metrics compare to the industry average?

What is the current P/B ratio for Ocular Therapeutix Inc (OCUL) as of Jan 08 2026?

As of Jan 08 2026, Ocular Therapeutix Inc (OCUL) has a P/B ratio of 8.01. This indicates that the market values OCUL at 8.01 times its book value.

What is the current FCF Yield for Ocular Therapeutix Inc (OCUL) as of Jan 08 2026?

As of Jan 08 2026, Ocular Therapeutix Inc (OCUL) has a FCF Yield of -7.92%. This means that for every dollar of Ocular Therapeutix Inc’s market capitalization, the company generates -7.92 cents in free cash flow.

What is the current Forward P/E ratio for Ocular Therapeutix Inc (OCUL) as of Jan 08 2026?

As of Jan 08 2026, Ocular Therapeutix Inc (OCUL) has a Forward P/E ratio of -8.49. This means the market is willing to pay $-8.49 for every dollar of Ocular Therapeutix Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Ocular Therapeutix Inc (OCUL) as of Jan 08 2026?

As of Jan 08 2026, Ocular Therapeutix Inc (OCUL) has a Forward P/S ratio of 41.74. This means the market is valuing OCUL at $41.74 for every dollar of expected revenue over the next 12 months.

OCUL Valuation